Does Transcranial Magnetic Stimulation of the Cingulate Cortex Modulate the Perception of Dyspnoea?

NCT00830921 | Terminated

• 1 other identifier: 07/Q1607/48
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The treatment we are studying is Transcranial Magnetic Stimulation (TMS). In TMS, an electromagnetic pulse is passed into the brain through a coil placed on the head. Previous studies have shown TMS to be capable of altering brain activity in specific areas; for example it has been used to improve mood in clinical depression. In this study we will assess if, by targeting TMS to the brain area responsible for feeling breathless, participants' breathlessness will be improved

Conditions

Malignancy

Keywords

Histocytologically proven thoracic malignancy

Study Arms (1)

1

Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services. Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept.

Device: Transcranial Magnetic Stimulation

Interventions

Transcranial Magnetic Stimulation DEVICE

Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients attending out-patient clinic

You may qualify if:

• Refractory dyspnoea (persisting sensation of air hunger despite optimisation of medical treatment)
• Histocytologically proven thoracic malignancy
• Written informed consent

You may not qualify if:

• Age \<18 years
• Left-handed
• Structural brain disease (including cerebral metastasis)
• Personal or family history of seizures
• Implantable metallic objects e.g. a pacemaker, or other contraindication to transcranial magnetic stimulation
• Pregnant or breast feeding
• Previous electroconvulsive therapy (ECT)
• Poor mobility
• Visual impairment
• Lack of social support / home to go to after the study treatment
• Alcohol dependency
• PaCO2 \>6kPa at rest
• Inability to provide informed consent

Sponsors & Collaborators

• University of Oxford: lead

Study Sites (1)

Oxford Centre for Respiratory Medicine

Oxford, OX3 7LJ, United Kingdom

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Transcranial Magnetic Stimulation

Intervention Hierarchy (Ancestors)

Magnetic Field Therapy; Therapeutics

Study Officials

• Robert Davies

  Oxford Centre For Respiratory Medicine

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2009
• First Posted: January 28, 2009
• Study Start: February 1, 2008
• Study Completion: January 1, 2012
• Last Updated: June 18, 2012

Record last verified: 2012-06

Locations

GB (1)